In SNI-operated male mice, intraperitoneal ACY-1215 (Rocilinostat) ameliorated pain compared with SNI alone, with relatively stable efficacy developing during treatment. A separate comparison with DMSO-treated SNI-operated mice showed reduced p-STAT3 expression following ACY-1215 (Rocilinostat) treatment. In mice injected with SK-N-BE(2) cells, the vehicle-control-versus-ACY-1215 (Rocilinostat) comparison reported fewer lesions in the liver, kidney, adrenal gland, and bone. [2,3]
Mechanical pain responses in mice after SNI surgery
Animal study · male mice; CD-1 mice; SNI-operated mice; n = 8 mice per group [2]
SNI-operated male mice received daily intraperitoneal ACY-1215 (Rocilinostat). Compared with SNI alone, treatment ameliorated SNI-induced pain assessed by von Frey testing, with efficacy becoming relatively stable during treatment.
Conditions shared by the study groups
- Route
- intraperitoneally
- Treatment course
- starting from day 1 post-SNI and continued daily until day 13
- Vehicle
- 10% DMSO in saline
- ACY-1215 (Rocilinostat) 20 mg/kg/day
- Model: male mice; CD-1 mice; SNI-operated mice; n = 8 mice per group
Methods and source locations
Compound reported in the paper: ACY-1215 (Rocilinostat); Compound label in the paper: ACY-1215
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Animals (S1); Materials and methods > Establishment of spared nerve injury (SNI) model (S15); Results > HDAC6 inhibitor ACY-1215 ameliorated neuropathic pain in SNI-operated mice (S90, S94, S95, S97, S99, S100, S102)
Mechanical thresholds for different groups of male mice in von Frey tests: Mechanical thresholds for different groups of male mice in von Frey tests; comparator: vehicle (10% DMSO in saline) — Results > HDAC6 inhibitor ACY-1215 ameliorated neuropathic pain in SNI-operated mice (S94, S97, S99)
ACY-1215 (Rocilinostat) 20 mg/kg/day · Results > HDAC6 inhibitor ACY-1215 ameliorated neuropathic pain in SNI-operated mice (S90, S94, S97)
Distant organ lesions in mice injected with neuroblastoma cells
Animal study · Mice injected with NB cells via tail vein; SK-N-BE(2) cells; n = 5 mice per group [3]
Mice injected with SK-N-BE(2) cells via the tail vein received daily intraperitoneal ACY-1215 (Rocilinostat) or vehicle. The control-versus-ACY-1215-treated comparison reported fewer lesions in distant organs, including the liver, kidney, adrenal gland, and bone.
Conditions shared by the study groups
- Route
- intraperitoneal administration
- Treatment course
- daily; 4-week endpoint
- Vehicle
- vehicle
- ACY-1215 (Rocilinostat) 30 mg/kg
- Model: Mice injected with NB cells via tail vein; SK-N-BE(2) cells; n = 5 mice per group
Methods and source locations
Compound reported in the paper: ACY-1215 (Rocilinostat); Compound label in the paper: ACY-1215
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Methods > Metastatic NB Model (S76, S78); Results > Targeting TCF4 Degradation with ACY-1215 Suppressed NB Metastasis (S188); Figure 6. legend (S301, S302, S304)
Quantification of metastatic foci in liver and kidney, and incidence of bone metastasis: Quantification of metastatic foci in liver and kidney, and incidence of bone metastasis; comparator: vehicle (control) — Methods > Metastatic NB Model (S76); Results > Targeting TCF4 Degradation with ACY-1215 Suppressed NB Metastasis (S188); Figure 6. legend (S304)
ACY-1215 (Rocilinostat) 30 mg/kg · Methods > Metastatic NB Model (S76, S78); Results > Targeting TCF4 Degradation with ACY-1215 Suppressed NB Metastasis (S188)
Phosphorylated STAT3 expression in SNI-operated male mice
Animal study · CD-1 mice; SNI-operated male mice; n = 5 [2]
SNI-operated male mice received intraperitoneal ACY-1215 (Rocilinostat). Treatment reduced p-STAT3 expression compared with SNI-operated mice receiving DMSO.
Conditions shared by the study groups
- Route
- intraperitoneally
- Treatment course
- for 14 consecutive days; On the 14th-day post-SNI
- Vehicle
- 10% dimethyl sulfoxide (DMSO)
- ACY-1215 (Rocilinostat) 20 mg/kg/day
- Model: CD-1 mice; SNI-operated male mice; n = 5
Methods and source locations
Compound reported in the paper: ACY-1215 (Rocilinostat); Compound label in the paper: ACY-1215
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Animals (S1); Materials and methods > Chemicals and antibodies (S6); Materials and methods > Establishment of spared nerve injury (SNI) model (S15); Results > HDAC6 inhibitor ACY-1215 ameliorated neuropathic pain in SNI-operated mice (S90); Results > ACY-1215 increased STAT3 acetylation and decreased its phosphorylation in the spinal cord of SNI-operated mice (S104, S105, S112, S114, S116)
Relative (Rel.) expression levels of p-STAT3: Relative (Rel.) expression levels of p-STAT3; comparator: SNI + DMSO — Results > HDAC6 inhibitor ACY-1215 ameliorated neuropathic pain in SNI-operated mice (S90); Results > ACY-1215 increased STAT3 acetylation and decreased its phosphorylation in the spinal cord of SNI-operated mice (S104, S105, S114)
ACY-1215 (Rocilinostat) 20 mg/kg/day · Results > HDAC6 inhibitor ACY-1215 ameliorated neuropathic pain in SNI-operated mice (S90); Results > ACY-1215 increased STAT3 acetylation and decreased its phosphorylation in the spinal cord of SNI-operated mice (S104, S105, S112)